Carbohydrate response element binding protein (ChREBP) is a transcription factor involved in activating genes that encode enzymes of fatty acid biosynthesis in liver and adipose. It is believed to be a key controller of hepatic lipogenesis and has a partner MLX. One study used ChREBP antibodies to better understand the mechanisms of ChREBP transcription via promoter binding studies (1). They found that Oct1 is a transcriptional repressor of ChREBP via the POU binding site. The ChREBP antibody was used to identify a novel role for the MondaA (chREBP paralog) in liver intracellular phosphate homeostasis via its recruitment to the protein targeting to glycogen (PTG) promoter (2).
Immunocytochemistry/Immunofluorescence: CHREBP Antibody
ChREBP antibody also allowed researchers to validate the liver receptor homologue (LRH-1) protein as a key regulatory component of the hepatic glucose-sensing system needed for lipid and glucose metabolism (3). These results are encouraging because LRH-1 is being viewed as a potential drug target for liver disease but not much was known about how LRH-1 regulates glucose and fatty acid metabolism under physiological conditions. Studies with the curry component curcumin and the ChREBP antibody have found that curcumin’s beneficial effects upon high fat diet (HFD) induced insulin resistance and obesity is mediated through attenuating lipogenic gene expression pathways and adipose tissue inflammatory responses (4). These results were contrary to previous ones implicating the Wnt signaling pathway which was clearly shown not be curcumin-stimulated in this particular system. ChREBP antibody was also used in a nonalcoholic fatty liver disease (NAFLD) model with loss of insulin insensitivity to explore onset and timing of various abnormalities (5). Investigators were able to dissociate hepatic stenosis from insulin resistance.
Novus Biologicals offers various ChREBP reagents for your research needs including:
